Meeting
2024 ASCO Genitourinary Cancers Symposium
Financial toxicity from PARP inhibitors in castrate-resistant prostate cancer.
Authors
David Joseph Benjamin
Hoag Family Cancer Institute, Newport Beach, CA
David Joseph Benjamin , Nataniel Hernan Lester-Coll , Arash Rezazadeh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 54)
DOI
10.1200/JCO.2024.42.4_suppl.54
Abstract #
54
Poster Bd #
B11
Abstract Disclosures
Similar Posters
First Author: Elena Castro
Poster
2023 ASCO Quality Care Symposium
Perceptions of emerging PARP inhibitor (PARPi) data among practicing oncologists in prostate cancer.
First Author: Nicholas Moffett
Poster
2021 ASCO Annual Meeting
TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal
Poster
2017 ASCO Annual Meeting
Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Fatima Karzai